Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
Identifieur interne : 003301 ( Main/Exploration ); précédent : 003300; suivant : 003302Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
Auteurs : Theresa A. Zesiewicz [États-Unis] ; Kelly L. Sullivan [États-Unis] ; Robert A. Hauser [États-Unis] ; Juan Sanchez-Ramos [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Anticonvulsants (therapeutic use), Chorea, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Huntington Disease (drug therapy), Huntington Disease (physiopathology), Huntington disease, Huntington's disease, Keppra, Levetiracetam, Male, Middle Aged, Nervous system diseases, Pilot Projects, Piracetam (analogs & derivatives), Piracetam (therapeutic use), Severity of Illness Index, Treatment, chorea, levetiracetam.
- MESH :
- chemical , analogs & derivatives : Piracetam.
- chemical , therapeutic use : Anticonvulsants, Piracetam.
- drug therapy : Huntington Disease.
- physiopathology : Huntington Disease.
- Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Pilot Projects, Severity of Illness Index.
Abstract
The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21061
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002B43
- to stream Istex, to step Curation: 002B43
- to stream Istex, to step Checkpoint: 001D60
- to stream PubMed, to step Corpus: 002B28
- to stream PubMed, to step Curation: 002B28
- to stream PubMed, to step Checkpoint: 002B94
- to stream Ncbi, to step Merge: 001811
- to stream Ncbi, to step Curation: 001811
- to stream Ncbi, to step Checkpoint: 001811
- to stream Main, to step Merge: 004614
- to stream PascalFrancis, to step Corpus: 001896
- to stream PascalFrancis, to step Curation: 001425
- to stream PascalFrancis, to step Checkpoint: 001988
- to stream Main, to step Merge: 004A83
- to stream Main, to step Curation: 003301
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></author><author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.21061</idno><idno type="url">https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002B43</idno><idno type="wicri:Area/Istex/Curation">002B43</idno><idno type="wicri:Area/Istex/Checkpoint">001D60</idno><idno type="wicri:doubleKey">0885-3185:2006:Zesiewicz T:open:label:pilot</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16941461</idno><idno type="wicri:Area/PubMed/Corpus">002B28</idno><idno type="wicri:Area/PubMed/Curation">002B28</idno><idno type="wicri:Area/PubMed/Checkpoint">002B94</idno><idno type="wicri:Area/Ncbi/Merge">001811</idno><idno type="wicri:Area/Ncbi/Curation">001811</idno><idno type="wicri:Area/Ncbi/Checkpoint">001811</idno><idno type="wicri:doubleKey">0885-3185:2006:Zesiewicz T:open:label:pilot</idno><idno type="wicri:Area/Main/Merge">004614</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0021735</idno><idno type="wicri:Area/PascalFrancis/Corpus">001896</idno><idno type="wicri:Area/PascalFrancis/Curation">001425</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001988</idno><idno type="wicri:doubleKey">0885-3185:2006:Zesiewicz T:open:label:pilot</idno><idno type="wicri:Area/Main/Merge">004A83</idno><idno type="wicri:Area/Main/Curation">003301</idno><idno type="wicri:Area/Main/Exploration">003301</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title><author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-11">2006-11</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1998">1998</biblScope><biblScope unit="page" to="2001">2001</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno><idno type="DOI">10.1002/mds.21061</idno><idno type="ArticleID">MDS21061</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticonvulsants (therapeutic use)</term><term>Chorea</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Huntington Disease (drug therapy)</term><term>Huntington Disease (physiopathology)</term><term>Huntington disease</term><term>Huntington's disease</term><term>Keppra</term><term>Levetiracetam</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Pilot Projects</term><term>Piracetam (analogs & derivatives)</term><term>Piracetam (therapeutic use)</term><term>Severity of Illness Index</term><term>Treatment</term><term>chorea</term><term>levetiracetam</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Piracetam</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>Piracetam</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Severity of Illness Index</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chorée Huntington</term><term>Chorée syndrome</term><term>Lévétiracétam</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li></region><settlement><li>Tampa</li></settlement><orgName><li>Université de Floride du Sud</li></orgName></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name></region><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003301 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003301 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B
|texte= Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
}}
| This area was generated with Dilib version V0.6.23. |  |